Skip to main content
Erschienen in: Clinical Drug Investigation 6/2014

01.06.2014 | Original Research Article

Availability of Data on Adverse Reactions to Antiretroviral Drugs in Medical Charts According to the Naranjo Algorithm: An Example of a Brazilian Historical Cohort

verfasst von: Cristiane A. Menezes de Pádua, Cristiano S. Moura

Erschienen in: Clinical Drug Investigation | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Background and Objective

Although not designed for research purposes, medical charts can be a unique source for obtaining information on long-term adverse drug reactions. This study aimed to assess the availability of key information on paper-based patient medical records needed to detect long-term adverse reactions to antiretroviral therapy (ART).

Methods

This is an ongoing historical cohort study carried out in three public HIV/AIDS referral centers in Belo Horizonte, Brazil. Medical charts of treatment-naïve HIV-infected adult patients initiating ART between 2001 and 2005 were reviewed for a follow-up period of up to 5 years after the first ART prescription. Descriptive analysis was performed by estimating the absolute and relative frequencies of selected variables. The Naranjo algorithm was employed to assess the availability of data on long-term adverse outcomes in medical charts.

Results

A total of 233 medical charts were eligible for study and 26.1 % contained at least one long-term adverse reaction, corresponding to 45 cases of dyslipidemia (19.3 %), 16 (6.9 %) of lipodystrophy and 5 of type 2 diabetes mellitus (2.1 %). Temporal relationship and ART switch could be better documented from medical charts. Information on reasons for ART switching and alternative causes for adverse reactions was very lacking.

Conclusions

Specific tools should be developed and included in medical routines to improve adverse reaction reporting by physicians and other health professionals. This could be implemented simultaneously with the transition from paper to electronic medical charts in Brazil, facilitating the identification of long-term adverse reactions to antiretroviral drugs in epidemiological studies and in clinical practice.
Literatur
1.
Zurück zum Zitat De Waal R, Cohen K, Maartens G. Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction. PLoS ONE. 2013;8(5):e63623.PubMedCentralPubMedCrossRef De Waal R, Cohen K, Maartens G. Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction. PLoS ONE. 2013;8(5):e63623.PubMedCentralPubMedCrossRef
2.
Zurück zum Zitat De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care. 2008;31(6):1224–9.PubMedCentralPubMedCrossRef De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care. 2008;31(6):1224–9.PubMedCentralPubMedCrossRef
3.
Zurück zum Zitat Härmark L, van Grootheest AC. Pharmacovigilance: methods, recent developments and future perspectives. Eur J Clin Pharmacol. 2008;64(8):743–52.PubMedCrossRef Härmark L, van Grootheest AC. Pharmacovigilance: methods, recent developments and future perspectives. Eur J Clin Pharmacol. 2008;64(8):743–52.PubMedCrossRef
4.
Zurück zum Zitat Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385–96.PubMedCrossRef Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385–96.PubMedCrossRef
5.
Zurück zum Zitat Olsen J. Using secondary data. In: Rothman K, Greenland S, editors. Modern epidemiology. 2nd ed. Philadelphia: Lippincott-Raven; 1998. p. 481–91. Olsen J. Using secondary data. In: Rothman K, Greenland S, editors. Modern epidemiology. 2nd ed. Philadelphia: Lippincott-Raven; 1998. p. 481–91.
6.
Zurück zum Zitat Murff HJ, Patel VL, Hripcsak G, Bates DW. Detecting adverse events for patient safety research: a review of current methodologies. J Biomed Inf. 2003;36(1–2):131–43.CrossRef Murff HJ, Patel VL, Hripcsak G, Bates DW. Detecting adverse events for patient safety research: a review of current methodologies. J Biomed Inf. 2003;36(1–2):131–43.CrossRef
7.
Zurück zum Zitat Gearing RE, Mian IA, Barber J, Ickowicz A. A methodology for conducting retrospective chart review research in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry. 2006;15(3):126–34.PubMedCentralPubMed Gearing RE, Mian IA, Barber J, Ickowicz A. A methodology for conducting retrospective chart review research in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry. 2006;15(3):126–34.PubMedCentralPubMed
8.
Zurück zum Zitat Agbabiaka TB, Savovic J, Ernst E. Methods for causality assessment of adverse drug reactions: a systematic review. Drug Saf. 2008;31(1):21–37.PubMedCrossRef Agbabiaka TB, Savovic J, Ernst E. Methods for causality assessment of adverse drug reactions: a systematic review. Drug Saf. 2008;31(1):21–37.PubMedCrossRef
9.
Zurück zum Zitat Greco DB, Simão M. Brazilian policy of universal access to AIDS treatment: sustainability challenges and perspectives. AIDS. 2007;21(Suppl 4):S37–45.PubMedCrossRef Greco DB, Simão M. Brazilian policy of universal access to AIDS treatment: sustainability challenges and perspectives. AIDS. 2007;21(Suppl 4):S37–45.PubMedCrossRef
13.
Zurück zum Zitat Standards of Medical Care in Diabetes. 2013. Diabetes Care. 2013;36(Suppl 1):S11–66. Standards of Medical Care in Diabetes. 2013. Diabetes Care. 2013;36(Suppl 1):S11–66.
14.
Zurück zum Zitat Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.PubMedCrossRef Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.PubMedCrossRef
15.
Zurück zum Zitat Heath KV, Hogg RS, Singer J, Chan KJ, O’Shaughnessy MV, Montaner JS. Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based cohort. J Acquir Immune Defic Syndr. 2002;30(4):440–7.PubMedCrossRef Heath KV, Hogg RS, Singer J, Chan KJ, O’Shaughnessy MV, Montaner JS. Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based cohort. J Acquir Immune Defic Syndr. 2002;30(4):440–7.PubMedCrossRef
16.
Zurück zum Zitat Pinto Neto LFS, Neves MB, Ribeiro-Rodrigues R, Page K, Miranda AE. Dyslipidemia and fasting glucose impairment among HIV patients three years after the first antiretroviral regimen in a Brazilian AIDS outpatient clinic. Braz J Infect Dis. 2013;17:438–43.PubMedCrossRef Pinto Neto LFS, Neves MB, Ribeiro-Rodrigues R, Page K, Miranda AE. Dyslipidemia and fasting glucose impairment among HIV patients three years after the first antiretroviral regimen in a Brazilian AIDS outpatient clinic. Braz J Infect Dis. 2013;17:438–43.PubMedCrossRef
17.
Zurück zum Zitat Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet. 2000;356(9239):1423–30.PubMedCrossRef Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet. 2000;356(9239):1423–30.PubMedCrossRef
19.
Zurück zum Zitat Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS. 2003;17(Suppl 1):S141–8.PubMedCrossRef Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS. 2003;17(Suppl 1):S141–8.PubMedCrossRef
20.
Zurück zum Zitat Masia-Canuto M, Bernal-Morell E, Gutierrez-Rodero F. Alteraciones lipidicas y riesgo cardiovascular asociado a la terapia antirretroviral. Enferm Infecc Microbiol Clin. 2006;24(10):637–48.PubMedCrossRef Masia-Canuto M, Bernal-Morell E, Gutierrez-Rodero F. Alteraciones lipidicas y riesgo cardiovascular asociado a la terapia antirretroviral. Enferm Infecc Microbiol Clin. 2006;24(10):637–48.PubMedCrossRef
21.
Zurück zum Zitat Brown TT, Glesby MJ. Management of the metabolic effects of HIV and HIV drugs. Nat Rev Endocrinol. 2012;8(1):11–21.CrossRef Brown TT, Glesby MJ. Management of the metabolic effects of HIV and HIV drugs. Nat Rev Endocrinol. 2012;8(1):11–21.CrossRef
23.
Zurück zum Zitat Silva FG, Tavares-Neto J. Avaliação dos prontuários médicos de hospitais de ensino do Brasil. Rev Bras Educ Med. 2007;31:113–26.CrossRef Silva FG, Tavares-Neto J. Avaliação dos prontuários médicos de hospitais de ensino do Brasil. Rev Bras Educ Med. 2007;31:113–26.CrossRef
Metadaten
Titel
Availability of Data on Adverse Reactions to Antiretroviral Drugs in Medical Charts According to the Naranjo Algorithm: An Example of a Brazilian Historical Cohort
verfasst von
Cristiane A. Menezes de Pádua
Cristiano S. Moura
Publikationsdatum
01.06.2014
Verlag
Springer International Publishing
Erschienen in
Clinical Drug Investigation / Ausgabe 6/2014
Print ISSN: 1173-2563
Elektronische ISSN: 1179-1918
DOI
https://doi.org/10.1007/s40261-014-0187-0

Weitere Artikel der Ausgabe 6/2014

Clinical Drug Investigation 6/2014 Zur Ausgabe